Tvardi Therapeutics is a clinical-stage Texas biotech that listed through a reverse merger with Cara Therapeutics and then watched its lead fibrosis study fail to show a lung-function benefit. The equity debate is no longer whether first-generation TTI-101 becomes an idiopathic pulmonary fibrosis drug. It is whether a phosphate prodrug of the same molecule, plus a still-open liver-cancer readout, can recast a thin cash balance into a credible STAT3 platform after that miss. Management has already moved the story: ulcerative colitis is now the designated first disease for the next-generation compound, and the remaining TTI-101 work is concentrated in hepatocellular carcinoma.
That reset is scientifically coherent and financially unfinished. Healthy-volunteer data released in July showed the prodrug converts quickly, matches parent-drug exposure, and shortens the diarrhea that limited TTI-101, with exploratory cuts in immune-cell subsets linked to colitis. Those are mechanism and tolerability findings in people who do not have the disease. They do not replace a patient study, and the planned colitis trial is conditioned on both a new investigational application and capital the present plan does not fund. Meanwhile the second-quarter statements still carry substantial doubt about going concern, even after an at-the-market program began selling stock after quarter-end.
Cash at mid-year was about $16 million against a first-half operating outflow of roughly $15 million. Subsequent market sales added about $13 million of gross proceeds and lifted the share count from about nine million to roughly thirteen million by mid-August. The late-year liver-cancer topline is the dated event that can change how that cash is valued. The open question is whether that readout, or a partner, arrives before the ATM and the going-concern language become the whole story.